Search results for "PLACEBO"

showing 10 items of 704 documents

Meta-analysis

2012

Treatment of the pain caused by chronic pancreatitis (CP) is not standardized. Knowledge of the response to placebo in this setting may aid the design of future trials. We aimed at investigating the placebo effect on abdominal pain remission rates in patients with CP.MEDLINE, EMBASE, and Scopus were searched, and randomized placebo-controlled trials in CP providing data on abdominal pain remission rates in placebo arms were included. Pooled estimates of the placebo rate were calculated using random-effects logistic regression analysis. Stratum-specific rates for different patients and study-level covariates were calculated to account for heterogeneity.Seven randomized controlled trials (202…

AdultMaleAbdominal painmedicine.medical_specialtyMEDLINEEndocrinology Diabetes and MetabolismPlaceboPlacebosEndocrinologyText miningDouble-Blind MethodPancreatitis ChronicInternal medicineInternal MedicinemedicineHumansIn patientRandomized Controlled Trials as TopicHepatologybusiness.industryMiddle AgedPlacebo Effectmedicine.diseaseAbdominal PainSurgeryClinical trialLogistic ModelsResearch DesignMeta-analysisPancreatitisFemaleAnalgesiamedicine.symptombusinessPancreas
researchProduct

Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia.

2017

We hypothesized that concomitant pharmacological inhibition of the endothelin and adenosine pathway is safe and improves exercise performance in hypoxic humans, via a mechanism that does not involve augmentation of blood oxygenation. To test this hypothesis, we established safety and drug interactions for aminophylline (500 mg) plus ambrisentan (5 mg) in normoxic volunteers. Subsequently, a placebo‐controlled study was employed to test the combination in healthy resting and exercising volunteers at simulated altitude (4,267 m). No serious adverse events occurred. Drug interaction was minimal or absent. Aminophylline alleviated hypoxia‐induced headaches. Aminophylline, ambrisentan, and their…

AdultMaleAdenosineAmbrisentanAdolescent030204 cardiovascular system & hematologyPharmacologyPlaceboHypoxemia03 medical and health sciencesYoung Adult0302 clinical medicineDouble-Blind MethodmedicineHumansPharmacology (medical)Adverse effectHypoxiaExercisePharmacologyPhenylpropionatesbusiness.industryAltitudeEndothelinsResearchArticlesHypoxia (medical)Drug interactionMiddle AgedAminophylline3. Good healthPyridazinesAnesthesiaAminophyllineDrug Therapy CombinationFemalemedicine.symptomEndothelin receptorbusiness030217 neurology & neurosurgerymedicine.drugSignal TransductionClinical pharmacology and therapeutics
researchProduct

Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine.

1998

A six-week double-blind placebo-controlled trial of fluvoxamine was undertaken in 46 patients suffering from panic disorder with or without agoraphobia diagnosed by DSM-III-R guidelines. Average daily dosage of fluvoxamine was 160 mg, with a highest permitted dose of 300 mg/day. Weekly evaluation included a diary in which the number, severity, and duration of full-blown and limited panic attacks and the duration and severity of anticipating fear, CAS, GAS, CGI, HAM-D, adverse effects and the number of capsules not taken were noted. Fluvoxamine was not significantly superior to placebo with regard to the main outcome criterion, i.e., the reduction in the number of panic attacks, but it was s…

AdultMaleAdolescentFluvoxaminePlacebolaw.inventionRandomized controlled trialDouble-Blind Methodlawmental disordersmedicineHumansPharmacology (medical)Adverse effectAgedPsychiatric Status Rating ScalesPanic disorderPanicGeneral MedicineMiddle Agedmedicine.diseasehumanitiesPsychiatry and Mental healthAnti-Anxiety AgentsFluvoxamineAnesthesiaPanic DisorderFemalemedicine.symptomDrug MonitoringPsychologyAnxiety disorderSelective Serotonin Reuptake Inhibitorsmedicine.drugAgoraphobiaPharmacopsychiatry
researchProduct

Effects of a single session of SMR neurofeedback training on anxiety and cortisol levels.

2020

Objectives: According to some studies, a putatively calming effect of EEG neurofeedback training could be useful as a therapeutic tool in psychiatric practice. With the aim of elucidating this possibility, we tested the efficacy of a single session of ¿sensorimotor (SMR)/¿theta neurofeedback training for mood improvement in 32 healthy men, taking into account trainability, independence and interpretability of the results. Methods: A pre-post design, with the following dependent variables, was applied: (i) psychometric measures of mood with regards to anxiety, depression, and anger (Profile of Mood State, POMS, and State Trait Anxiety Inventory, STAI); (ii) biological measures (salivary leve…

AdultMaleAdolescentHydrocortisonePsychometricsmedia_common.quotation_subjectAnxietyAngerElectroencephalographyPlacebo050105 experimental psychologyYoung Adult03 medical and health sciences0302 clinical medicinePhysiology (medical)HumansMedicine0501 psychology and cognitive sciencesTheta RhythmDepression (differential diagnoses)media_commonSimulació Mètodes demedicine.diagnostic_testbusiness.industry05 social sciencesBrainGeneral MedicineNeurofeedbackAffectAnsietatMoodNeurologyAnxietyNeurology (clinical)medicine.symptomNeurofeedbackBeta Rhythmbusiness030217 neurology & neurosurgeryState-Trait Anxiety InventoryClinical psychology
researchProduct

Clinical evaluation of antiseptic mouth rinses to reduce salivary load of SARS-CoV-2

2021

AbstractMost public health measures to contain the COVID-19 pandemic are based on preventing the pathogen spread, and the use of oral antiseptics has been proposed as a strategy to reduce transmission risk. The aim of this manuscript is to test the efficacy of mouthwashes to reduce salivary viral load in vivo. This is a multi-centre, blinded, parallel-group, placebo-controlled randomised clinical trial that tests the effect of four mouthwashes (cetylpyridinium chloride, chlorhexidine, povidone-iodine and hydrogen peroxide) in SARS-CoV-2 salivary load measured by qPCR at baseline and 30, 60 and 120 min after the mouthrinse. A fifth group of patients used distilled water mouthrinse as a contr…

AdultMaleAdolescentScienceMouthwashesArticleMalalties transmissibles PrevencióYoung AdultDouble-Blind Methodstomatognathic systemHumansChildSalivaAgedMultidisciplinarySARS-CoV-2QRInfant NewbornCOVID-19InfantMiddle AgedViral LoadPlacebo EffectVirusViral infectionChild PreschoolRandomized controlled trialsAnti-Infective Agents LocalMedicineFemale
researchProduct

Analgesic efficacy of ketorolac associated with a tramadol/acetaminophen combination after third molar surgery - a randomized, triple-blind clinical …

2019

Background This study compared the efficacy of ketorolac alone versus its combination with tramadol/acetaminophen for pain control after mandibular third molar surgery. Material and Methods A randomized, triple-blind clinical trial was carried out with 52 patients divided into 2 groups: Group K+T+A (1 tablet of Ketorolac 10 mg plus and 1 capsule of Tramadol 37.5 mg/acetaminophen 325 mg) and Group K (1 tablet of Ketorolac 10 mg plus and 1 placebo capsule). The treatments were given 1 h before the surgery and was repeated 4 times per day, for 48 h. The difference in postoperative pain was assessed by 4 primary end-points: pain intensity (VAS 100mm, for 48 h), rescue medication, overall assess…

AdultMaleAdolescentmedicine.drug_classAnalgesicPlacebolaw.inventionYoung Adult03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled triallawHumansMedicineAntiemeticAdverse effectGeneral DentistryTramadolAcetaminophenPain Postoperativebusiness.industryResearchAnti-Inflammatory Agents Non-Steroidal030206 dentistryAnalgesics Non-Narcotic:CIENCIAS MÉDICAS [UNESCO]AcetaminophenAnalgesics OpioidKetorolacTreatment OutcomeOtorhinolaryngologyAnesthesiaUNESCO::CIENCIAS MÉDICASTooth ExtractionDrug Therapy CombinationFemaleMolar ThirdSurgeryTramadolAnalgesiaOral SurgerybusinessKetorolac030217 neurology & neurosurgerymedicine.drugMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Microbiological effects of an antiseptic mouthrinse in irradiated cancer patients

2010

Objective: To assess the microbiological effects of an antiseptic, non-alcohol based mouth-rinse containing chlorhexidine and cetylpyridinium chloride, in patients undergoing radiation therapy for head-and-neck cancer. Study Design: This was a parallel, double-blind, prospective, randomized clinical trial, including patients irradiated as part of the therapy of head-and-neck cancer, aged 18-75, with at least 10 teeth, and willing to sign an informed consent. Cancer patients were randomly assigned to one of the two treatments (test mouth-rinse or a placebo). Three visits were scheduled (baseline, 14 and 28 days). Microbiological findings were evaluated in tongue, mucosa and subgingival sampl…

AdultMaleAdolescentmedicine.drug_classmedicine.medical_treatmentMouthwashesDentistryCetylpyridiniumPlacebolaw.inventionYoung AdultAntisepticRandomized controlled trialDouble-Blind MethodlawTongueMedicineHumansProspective StudiesProspective cohort studyGeneral DentistryAgedMouthbusiness.industryChlorhexidineChlorhexidineCancerMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Radiation therapymedicine.anatomical_structureOtorhinolaryngologyHead and Neck NeoplasmsUNESCO::CIENCIAS MÉDICASAnti-Infective Agents LocalSurgeryFemalebusinessmedicine.drug
researchProduct

The Endogenous Opioid System Is Not Involved in Modulation of Opioid-Induced Hyperalgesia

2009

Abstract Some recent studies suggested a role of the endogenous opioid system in modulating opioid-induced hyperalgesia (OIH). In order to test this hypothesis, we conducted a prospective randomized, placebo-controlled, 2-way crossover study in healthy human volunteers. We utilized a well-established model of inducing OIH after a brief exposure to the μ-opioid agonist remifentanil using intradermal electrical stimulation. Patients were exposed to a randomized 90-minute infusion of remifentanil or saline placebo during 2 separate occasions. Development of OIH was quantified using changes in the average radius of the area of secondary hyperalgesia generated by electrical pain stimulation. A 2…

AdultMaleAgonistmedicine.drug_classNarcotic AntagonistsRemifentanilBlood PressureStimulationPharmacologyPlaceboRemifentanilYoung AdultDouble-Blind MethodPiperidinesHeart RatemedicineHumansOpioid-induced hyperalgesiaPain MeasurementEndogenous opioidCross-Over StudiesNaloxonebusiness.industryMiddle AgedAnalgesics OpioidAnesthesiology and Pain MedicineNeurologyOpioidHyperalgesiaAnesthesiaHyperalgesiaNeurology (clinical)medicine.symptombusinessmedicine.drugThe Journal of Pain
researchProduct

BASALIT trial: double-blind placebo-controlled allergen immunotherapy with rBet v 1-FV in birch-related soya allergy.

2016

Background Conflicting results exist on the effect of allergen immunotherapy (AIT) on pollen-related food allergy. We aimed to investigate the efficacy of one-year AIT with the folding variant (FV) of recombinant (r) Bet v 1 on birch-related soya allergy. Methods Of 138 subjects with Bet v 1 sensitization, 82 were positive at double-blind placebo-controlled food challenge (DBPCFC) with soya. A total of 56 of 82 were randomized in the ratio of 2:1 (active: placebo). Per-protocol population (PPP) had received ≥150 μg of allergen or placebo preparation. Outcome measures: lowest observed adverse effect levels (LOAEL), postinterventional occurrence of objective signs (objS) at any dose level, sI…

AdultMaleAllergen immunotherapymedicine.medical_specialtyAllergyImmunologyPopulationmedicine.disease_causePlaceboGastroenterology030207 dermatology & venereal diseases03 medical and health sciencessymbols.namesake0302 clinical medicineAllergenFood allergyStatistical significanceInternal medicinemedicineImmunology and AllergyHumanseducationFisher's exact testBetulaSkin Testseducation.field_of_studybusiness.industryRhinitis Allergic SeasonalAntigens PlantImmunoglobulin EMiddle Agedmedicine.diseaseTreatment Outcome030228 respiratory systemDesensitization ImmunologicImmunologysymbolsQuality of LifeFemaleSoybeansbusinessFood HypersensitivityAllergy
researchProduct

Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study.

2014

Abstract Introduction Epistaxis is the most frequent manifestation in hereditary hemorrhagic telangiectasia, in which no optimal treatment exists. It can lead to severe anemia and reduced quality of life. Positive effects of tranexamic acid, an antifibrinolytic drug, have been reported on epistaxis related to this disorder. We sought to evaluate the efficacy of treating nosebleeds in hereditary hemorrhagic telangiectasia with tranexamic acid. Materials and Methods In a randomized, double-blind, placebo controlled, cross-over phase IIIB study, 1 gram of tranexamic acid or placebo was given orally 3 times daily for 3 months for a total of 6 months. Results 22 patients were included in the int…

AdultMaleAntifibrinolyticTime Factorsmedicine.drug_classMedizinAdministration OralPlaceboDrug Administration ScheduleDouble blindQuality of lifeDouble-Blind MethodGermanymedicineHumansTelangiectasiaAgedDiminutionCross-Over Studiesbusiness.industryHematologyMiddle AgedAntifibrinolytic AgentsClinical trialEpistaxisTreatment OutcomeTranexamic AcidAnesthesiaFemaleTelangiectasia Hereditary Hemorrhagicmedicine.symptombusinessTranexamic acidmedicine.drugThrombosis research
researchProduct